Mr. Jean-Marc Leveille reports

KDA GROUP SALUTES THE EXCEPTIONAL CONTRIBUTION OF THE CHU DE QUEBEC - UNIVERSITE LAVAL TO THE MEDHERIZE PILOT PROJECT AND CONFIRMS ITS INTENTION TO PURSUE THIS COLLABORATION

KDA Group Inc. has highlighted the publication, by the CHU de Quebec -- Universite Laval, of a post showcasing the results of the Medherize pilot project conducted at the Centre des maladies du sein, and to express its deep gratitude to the clinical, professional and administrative teams that made this project possible.

In its post entitled "L'innovation au coeur du parcours de soins | Des benefices tangibles" (Innovation at the heart of the care pathway | Tangible benefits), the CHU states that the Medherize pilot project "demonstrated the potential of digital solutions to optimize the follow-up of people receiving oral therapy for breast cancer" and that "the results obtained reflect greater efficiency in clinical processes, a significant reduction in certain follow-up tasks and a high level of satisfaction." The CHU thanks the teams of the Centre des maladies du sein as well as KDA, "the partner behind the Medherize solution."

An exemplary collaboration between the public network and a Quebec technology company

Deployed from September, 2025, to March, 2026, with 243 patients treated with CDK4/6 inhibitors, the pilot project was the subject of an independent quality-of-care evaluation (Pro-Acte) conducted by the CHU and completed on June 15, 2026. The evaluation notably found a patient adherence rate of 97 per cent, self-reported weekly compliance of 93 per cent, a 52-per-cent reduction in the workload of hospital pharmacists, and an 80-per-cent decrease in medical consultations and follow-up calls related to monitoring, with no transfer of workload to patients or to community pharmacies. All of the objectives set at the outset of the project were achieved.

"These results belong first and foremost to the teams of the Centre des maladies du sein of the CHU de Quebec -- Universite Laval. From day 1, the pharmacists, physicians, oncology nurse navigators and administrative staff agreed to question their ways of working, to confront us with the realities of the field and to measure rigorously, and independently, what worked and what needed to be improved. It is this rigour that gives the demonstration its full value. We are deeply grateful to them, as well as to the CHU's Bureau de l'innovation, which oversaw the project with exemplary discipline," said Jean-Marc Leveille, fellow CRIA, president and chief executive officer of KDA.

A shared commitment to pursue and broaden the collaboration

Medherize is a platform developed and hosted in Quebec that connects the hospital, the pharmacy and the patient to ensure targeted, safe follow-up of oral therapies, particularly in oncology. It is integrated with the Dossier sante Quebec and holds the Trousse globale de verification (TGV) certification of the Ministere de la Sante et des Services sociaux, valid until June, 2030.

KDA intends to maintain and deepen its collaboration with the CHU. The two organizations are continuing their discussions with a view to making Medherize a permanent fixture at the Centre des maladies du sein and to exploring new projects aimed at supporting medical teams and patients, including extending follow-up to other oral therapies and measuring the platform's effect on emergency department visits.

"The CHU has shown that a digital innovation designed with clinicians, for clinicians, can free up care time without compromising the quality or safety of follow-up. We want to build on this achievement, together with the CHU, so that other teams and other patients can benefit from it," added Mr. Leveille.

About KDA Group Inc.

KDA Group is a leader in technological innovations and specialized software solutions (SaaS -- software-as-a-service) for the health care professionals' market. KDA is a corporation that offers quality products and has respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the health care's digital transformation, and are available for the Canadian and international markets.

We seek Safe Harbor.